Ekaterina Silina | Drug Discovery | Research Excellence Award

Published on by Top Pharmaceutical

Prof. Dr. Ekaterina Silina | Drug Discovery | Research Excellence Award

Professor | Sechenov First Moscow State Medical University (Sechenov University) | Russia

Prof. Dr. Ekaterina Silina is a distinguished researcher in materials science, nanotechnology, and biomedical applications, with a strong focus on functional nanomaterials, sensors, and therapeutic platforms. Her work bridges advanced material synthesis with real-world medical and environmental applications, contributing significantly to high-impact interdisciplinary research. She has authored 165 documents, receiving 1,217 citations across 1,004 citing documents, and holds an h-index of 18, reflecting sustained scholarly influence and global research visibility.

Citation Metrics (Scopus)

1300

1000

800

600

400

200

0

Citations
1,217

Documents
165

h-index
18

        🟦 Citations    🟥 Documents    🟩 h-index


View Scopus Profile

Featured Publications

Xu Yufen | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Xu Yufen | Drug Discovery and Development | Best Researcher Award

The Affiliated Hospital of Jiaxing University | China

Dr. Xu Yufen, Ph.D. in Medicine and Associate Professor at Jiaxing University, has emerged as a dedicated academic and clinical researcher in the field of chest tumors, with a strong focus on lung cancer, esophageal cancer, and thymoma. Her academic and professional journey reflects a unique blend of clinical insight and rigorous scientific research, bridging traditional and modern medical practices to address some of the most pressing challenges in oncology.Her research portfolio encompasses multiple completed and ongoing projects, including significant contributions to the Zhejiang Provincial Science and Technology Program in Traditional Chinese Medicine and Jiaxing City’s Science and Technology Program. Presently, she is leading three active research projects aimed at developing innovative therapeutic strategies and improving patient outcomes in chest oncology. Her studies demonstrate a strong commitment to integrating clinical experience with advanced research methodologies, paving the way for evidence-based, patient-centered cancer care.Dr. Xu’s scholarly impact is reflected in her extensive publication record in high-quality journals indexed in SCI and Scopus. Notable works include Development and Validation of a Prognostic Nomogram for Early Stage Non-Small Cell Lung Cancer: A Study Based on the SEER Database and a Chinese Cohort, Effect of Postoperative Radiotherapy on Survival in Patients with Completely Resected and Pathologically Confirmed Stage N2 Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis, LncRNA HCG11 Enhances the Chemosensitivity of Non-Small Cell Lung Cancer Cells to Gemcitabine via miR-17-5p/p21 Axis, and Akkermansia Muciniphila Outer Membrane Protein Regulates Recruitment of CD8+ T Cells in Lung Adenocarcinoma and Through JAK–STAT Signalling Pathway. These publications highlight her expertise in clinical oncology research, molecular biology, and the exploration of novel therapeutic targets.Her contributions to the academic community extend beyond research. Dr. Xu has been actively involved in professional organizations such as the Second Youth Committee of the Cancer Support Treatment Committee of the Zhejiang Society of Mathematical Medicine, the Chinese Society of Clinical Oncology’s expert committee on integrated traditional and Western medicine, and the Youth Committee of the Zhejiang Medical Association Oncology Branch. Through these roles, she fosters collaboration, knowledge-sharing, and the translation of research findings into clinical practice.

Profile: Scopus

Featured Publications

Authors Unknown. (2024). Akkermansia muciniphila outer membrane protein regulates recruitment of CD8+ T cells in lung adenocarcinoma and through JAK–STAT signalling pathway. Microbial Biotechnology.

Authors Unknown. (n.d.). Research progress in the therapeutic application of traditional Chinese medicine for postoperative cough in patients with lung cancer. Journal Name Unknown.

Authors Unknown. (n.d.). LncRNA HCG11 enhances the chemosensitivity of non-small cell lung cancer cells to Gemcitabine via miR-17-5p/p21 axis. Expert Review of Anticancer Therapy.

Gaetan Ligat | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Gaetan Ligat | Drug Discovery and Development | Best Researcher Award

Assoc. Prof. Dr. Gaetan Ligat at Toulouse University | France

Assoc. Prof. Dr. Gaetan Ligat is a molecular virologist and principal investigator at Toulouse University, affiliated with INSERM UMR1291 and CNRS UMR5051. He leads the ViNeDys team at the Toulouse Institute for Infectious and Inflammatory Diseases, focusing on host–human cytomegalovirus interactions in brain tumors and therapeutic innovation. With extensive research and teaching experience across France, he has contributed to advancing antiviral strategies, mentoring young scientists, and promoting scientific communication. He is actively engaged in international collaborations, scientific societies, and community outreach, while securing multiple research grants to strengthen translational virology and oncology research.

Publication Profile 

Google Scholar

Education 

Assoc. Prof. Dr. Gaetan Ligat pursued his scientific training at Limoges University, France. He earned a Master of Science degree in Genetics and Physiology, which laid the foundation for his research career. He then advanced to doctoral studies at INSERM UMR1092, Limoges University, where he specialized in Molecular Virology, completing his PhD with distinction. His academic formation emphasized molecular biology, virus-host interactions, and translational virology, providing expertise in genetics, physiology, and applied biomedical sciences. This strong educational background enabled him to develop a career bridging fundamental research and therapeutic applications, particularly in virology, cancer biology, and innovative antiviral treatment strategies.

Experience 

Assoc. Prof. Dr. Gaetan Ligat is Associate Professor of Virology at Toulouse University, where he also serves as Principal Investigator and group leader of the ViNeDys team at the Infinity Institute. His work focuses on host–HCMV interactions and therapeutic innovation in brain tumors. Previously, he was a postdoctoral researcher at INSERM UMR1110 in Strasbourg, specializing in antiviral strategies. He began his research as a Master’s and PhD candidate at INSERM UMR1092, Limoges. Alongside research, he has coordinated training programs, practical courses, and supervised over 20 students. He is deeply involved in scientific societies, equality initiatives, and international collaborations.

Awards and Honors 

Assoc. Prof. Dr. Gaetan Ligat has received numerous prestigious recognitions, including the National Thesis Prize from the French Society of Microbiology and fellowships from the French National Agency for Research on AIDS and Viral Hepatitis (ANRS). He was awarded an ESCMID Research Grant, travel grants from the French Society of Microbiology, and registration bursaries for international congresses. His successful fundraising as principal investigator includes support from cancer foundations, patient associations, and Inserm/Regional PhD funding. These honors reflect both his scientific excellence and commitment to translational virology and oncology research. His awards highlight his impact on advancing antiviral and therapeutic research.

Research Focus 

Assoc. Prof. Dr. Gaetan Ligat research focuses on the molecular biology of human cytomegalovirus (HCMV) and its interaction with host cells, particularly in brain tumor environments. His work aims to understand how viral mechanisms contribute to disease progression and to identify novel therapeutic targets. He develops innovative antiviral strategies, including peptides and antibodies targeting HCMV protein interactions. His research also explores inflammatory responses, host-pathogen dynamics, and translational approaches for cancer treatment. Through collaborative projects and funded research programs, he seeks to bridge fundamental virology with therapeutic innovation, advancing the fight against viral infections and HCMV-related diseases in oncology.

Publication Top Notes

The human cytomegalovirus terminase complex as an antiviral target: a close-up view

Capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives

Hepatitis C virus (HCV)–apolipoprotein interactions and immune evasion and their impact on HCV vaccine design

Hepatitis B virus–host interactions and novel targets for viral cure

Hepatitis B virus core variants, liver fibrosis, and hepatocellular carcinoma

Targeting viral cccDNA for cure of chronic hepatitis B

The Yin and the Yang of extracellular vesicles during viral infections

Structures and divergent mechanisms in capsid maturation and stabilization following genome packaging of human cytomegalovirus and herpesviruses

Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: benefits and limits of 3D analysis

Interferon‐Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection

Identification of a short sequence in the HCMV terminase pUL56 essential for interaction with pUL89 subunit

Identification of amino acids essential for viral replication in the HCMV helicase-primase complex